Scott Alexander examines and expresses skepticism about a theory that attributes high-dose melatonin supplements to patent avoidance, while reflecting on the challenges of evaluating such claims.
Longer summary
Scott Alexander discusses a theory about why melatonin supplements are often sold in doses much higher than recommended. The theory, proposed by Dr. Richard Wurtman, suggests that supplement manufacturers used higher doses to avoid paying royalties on a patent for lower doses. Scott expresses skepticism about this explanation, citing reasons such as the unusualness of patenting only up to a certain dose and the fact that many supplements are sold in high doses. He also notes that some companies do sell melatonin at the recommended dose without legal issues. Scott reflects on the challenges of evaluating such claims, balancing expert knowledge against rational skepticism. An update clarifies that the patent likely influenced initial supplement production but has since expired, though high-dose traditions persist.
Shorter summary